Anteris Technologies Global Corp. — Proxy Solicitation & Information Statement 2025

Oct 15, 2025

==> picture [137 x 39] intentionally omitted <==

Annual Meeting Announcement

MINNEAPOLIS, United States and BRISBANE, Australia 16 October 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces that the Company will host its first Annual Meeting of Stockholders (the “Annual Meeting”) on December 3, 2025 (December 4, 2025 in Australia). The record date for the determination of stockholders of the Company entitled to notice of and to vote at the Annual Meeting is October 30, 2025 (October 31, 2025 in Australia). The Company will publish additional details regarding the exact time and matters to be voted on at the Annual Meeting in the Company’s proxy statement for the Annual Meeting.

In order for stockholder proposals to be presented at the Annual Meeting (including a proposal for election of directors), including by means of inclusion of a stockholder proposal in the proxy materials under Rule 14a-8 of the Securities Exchange Act of 1934, as amended, such proposals must be received by the Company’s Secretary a reasonable time before the Company begins to print and mail its proxy materials, which the Company has determined to be not later than October 25, 2025 at 11:59 p.m. Eastern time (2:59 p.m. AEDT on October 26, 2025 in Australia). Any proposal submitted after the above deadline will not be considered timely and will be excluded from the Company’s proxy materials. Proposals of stockholders must also comply with rules of the U.S. Securities and Exchange Commission (the “SEC”) regarding the inclusion of stockholder proposals in proxy materials and the Company may omit from its proxy materials any proposal that does not comply with the SEC’s rules. All stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting must also comply with applicable Delaware law and the procedures set forth in the Company’s Amended and Restated Bylaws.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a sciencedriven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR[®] Transcatheter Heart Valve ( THV ), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially lifethreatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[® ] THV is made using a single piece of molded ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

860 Blue Gentian Road, Suite 340 Eagan, MN, 55121 United States T: +1 651 493 0606 info.us@anteristech.com

Anteris Technologies Global Corp. BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

==> picture [28 x 30] intentionally omitted <==

Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong QLD 4066, Australia T: +61 1300 550 310 info.au@anteristech.com ARBN: 677 960 235

anteristech.com

==> picture [116 x 33] intentionally omitted <==

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Vice Chairman and CEO.

For more information:

Investor Relations

investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269

Website www.anteristech.com X @AnterisTech LinkedIn https://www.linkedin.com/company/anteristech

==> picture [28 x 30] intentionally omitted <==

2